Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPRES Extension: Long-term Imatinib in Severe Pulmonary Arterial Hypertension
jRCT2080221689Phase 3
- Sponsor
- Novartis
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of imatinib in pulmonary arterial hypertension (PAH), sponsored by Novartis.
02
Drugs
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on jRCT2080221689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221689.